Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (171)	4/9/2007 9:54:55 PM
From: tuck	Respond to of 312

[ApoB-100 as target in VLDL inhibition in HCV therapy] It is possible ISIS 301012, in development for hypercholesterolemia, would be the better choice over MTP inhibitors, given a pretty good safety profile to date (the authors make elliptical reference to it in the full text article). Although it would be contraindicated in patients that had HCV and hypocholesterolemia, for sure (but how many such people are out there?), and since VLDLs are essential to other functions, being overzealous in inhibiting them could have bad effects. Cheers, Tuck